Pfizer rolls out next-gen pneumococcal vaccine with FDA win, beating Merck's 15-valent candidate to the punch
Merck and Pfizer have been locked in a yearslong battle for a next-gen pneumococcal vaccine winner, with the latter looking to one-up — or should we say seven-up — its standard 13-valent shot. Now, Pfizer has nosed out a win with the FDA’s backing, leaving Merck and its 15-valent shot waiting in the wings.
Pfizer said on Tuesday that the FDA has approved its Prevnar 20 for adults 18 years and older — just over a month before Merck’s PDUFA date for its V114. The CDC’s Advisory Committee on Immunization Practices is scheduled to meet in October to discuss and update recommendations on the use of pneumococcal vaccines, according to Pfizer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.